How many institutional investors hold HALO?

4 tracked institutional investors disclosed a position in HALO (HALOZYME THERAPEUTICS INC) in their most recent 13F filing.

Who is the largest institutional holder of HALO?

Izzy Englander, Millennium Management, holds the largest disclosed position in HALO, valued at $102M.

Where does this HALO ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

HALO — HALOZYME THERAPEUTICS INC

Name: HALOZYME THERAPEUTICS INC (HALO) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About HALOZYME THERAPEUTICS INC (HALO)

HALOZYME THERAPEUTICS INC (HALO) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $102M. Across recent filings, tracked investors recorded 2 new positions, 1 increased, 1 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in HALO

/100

Institutional Accumulation

Added / Increased3

Reduced1

Exited0

BearishBullish

Crowded Trade Score™

How many top investors track HALO

/100

Emerging Interest

4investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

HALO Ownership Composition

How HALOZYME THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

57% of tracked value

Institutions

tracked investors

Total Reported

$142.6M

combined 13F value

Other57.3%
Hedge Funds42.7%

Other(3)

57.3%

Hedge Funds(1)

42.7%

Tracked investors reporting HALO

Investor	Firm	Shares	Market value	% of portfolio	As of
Izzy Englander	Millennium Management	471.3K	$30.5M	0.01%	Mar 31, 2026
Steve Cohen	Point72 Asset Management	47.4M	$60.9M	0.08%	Mar 31, 2026
Ken Griffin	Citadel Advisors	281.9K	$18.2M	0.00%	Mar 31, 2026
Ray Dalio	Bridgewater Associates	511.4K	$33.1M	0.15%	Mar 31, 2026

Izzy EnglanderMar 31, 2026
Millennium Management
Shares
471.3K
Value
$30.5M
% Portfolio
0.01%
Steve CohenMar 31, 2026
Point72 Asset Management
Shares
47.4M
Value
$60.9M
% Portfolio
0.08%
Ken GriffinMar 31, 2026
Citadel Advisors
Shares
281.9K
Value
$18.2M
% Portfolio
0.00%
Ray DalioMar 31, 2026
Bridgewater Associates
Shares
511.4K
Value
$33.1M
% Portfolio
0.15%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Steve Cohen	New	—	$60.9M	May 15, 2026
Ray Dalio	Reduced	-8.93%	$33.1M	May 15, 2026
Ray Dalio	Increased	15.29%	$37.8M	Feb 13, 2026
Ray Dalio	New	—	$35.7M	Nov 13, 2025

Steve Cohen
New
$60.9MMay 15, 2026
Ray Dalio
Reduced
$33.1M(-8.93%)May 15, 2026
Ray Dalio
Increased
$37.8M(15.29%)Feb 13, 2026
Ray Dalio
New
$35.7MNov 13, 2025

Frequently asked questions

How many institutional investors hold HALO?: 4 tracked institutional investors disclosed a position in HALO (HALOZYME THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of HALO?: Izzy Englander, Millennium Management, holds the largest disclosed position in HALO, valued at $102M.
Did institutional ownership of HALO increase or decrease?: Across recent 13F filings, tracked investors recorded 2 new positions, 1 increased, 1 reduced, and 0 fully exited HALO.
Where does this HALO ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.